CD44 is best known as a receptor for hyaluronan, a large sugar-rich molecule found in the extracellular matrix—the structural network that surrounds cells. When hyaluronan binds to CD44, it can activate intracellular signalling pathways that regulate proliferation, survival, migration and changes in cell identity. These signals may involve pathways such as PI3K–AKT, RAS–RAF–MEK–ERK, Wnt–β-catenin, NF-κB and YAP–TAZ. The result is a molecular system capable of translating physical and chemical changes in the tumour environment into instructions that help cancer cells adapt.

The receptor is also unusually complex because the CD44 gene can produce multiple protein forms through alternative splicing. The standard form, often called CD44s, is found in many normal tissues, while variant forms, known as CD44v, contain additional extracellular regions generated by the inclusion of variable exons. These variants can alter how the receptor interacts with growth factors, matrix components and signalling proteins. In several cancers, particular CD44 variants have been associated with aggressive disease, although their abundance and biological significance can differ between tumour types and even between regions of the same tumour.

One of the most closely studied functions of CD44 is its connection to cancer stem-like cells. These cells are not necessarily permanent or identical to stem cells in healthy tissue, but they can display enhanced abilities to self-renew, initiate new tumours and survive stress. CD44-positive populations have been reported in cancers including breast, colorectal, gastric, pancreatic, head and neck and liver malignancies. The review highlights that CD44 is not a universal or definitive cancer-stem-cell marker; instead, its importance depends on the tissue, the CD44 isoform, the surrounding microenvironment and the other markers present on the cell.

CD44 may also help cancer cells undergo epithelial–mesenchymal transition, or EMT, a developmental programme that can give stationary epithelial cells more mobile and invasive properties. During EMT-like changes, tumour cells may lose strong cell-to-cell adhesion and acquire the ability to move through tissue, enter blood vessels and establish distant colonies. CD44 signalling can interact with transcriptional regulators such as Snail, Slug, Twist and ZEB proteins, which are known to control EMT-associated gene expression. This interaction creates a potential molecular bridge between altered cell identity and metastatic behaviour.

The receptor’s effects extend beyond tumour cells themselves. CD44 is present on immune cells, fibroblasts and other stromal populations that occupy the tumour microenvironment. By influencing interactions among these cells, CD44 can contribute to a local environment that supports tumour growth. Its signalling has been linked to inflammatory responses, extracellular-matrix remodelling and the recruitment or functional alteration of immune populations. In some settings, these processes may reduce effective anti-tumour immunity, allowing malignant cells to persist despite the presence of immune surveillance.

Another concern is the relationship between CD44 and resistance to treatment. Cancer cells that express certain CD44 forms may be better equipped to withstand chemotherapy, radiation or targeted drugs through enhanced DNA-repair capacity, altered drug transport, antioxidant protection and survival signalling. CD44-positive cells can also occupy protected niches within tumours, where limited oxygen, nutrient changes and matrix interactions promote a more resilient state. These observations have made CD44 an attractive candidate for therapeutic intervention, but they also underline why simply eliminating CD44-bearing cells may not be sufficient.

Several strategies are being investigated to target the CD44 system. Antibodies and antibody–drug conjugates aim to recognise CD44 or selected CD44 variants and deliver toxic payloads directly to tumour cells. Hyaluronan-based nanoparticles and drug-delivery systems seek to exploit the receptor’s natural binding properties, potentially concentrating treatment in CD44-rich tumours. Other approaches attempt to block the interaction between CD44 and hyaluronan, inhibit downstream signalling, degrade hyaluronan in the tumour environment or target CD44-positive cancer stem-like populations. Each strategy faces technical barriers, including variable CD44 expression, the presence of the receptor in normal tissues and the difficulty of distinguishing malignant from healthy CD44-positive cells.

The review by Oh, Kim, Kim and colleagues presents CD44 as a promising but highly context-dependent therapeutic target. Its expression alone may not reliably predict prognosis or treatment response, because CD44 is shaped by alternative splicing, post-translational modification, cellular location and signals from the surrounding microenvironment. Future treatments may therefore need to combine CD44 targeting with immunotherapy, chemotherapy, radiation or inhibitors of specific signalling pathways. The broader message is that cancer biology cannot be reduced to a single marker: CD44 is better understood as a flexible molecular hub whose effects change with tumour type and disease stage. Mapping those differences could help researchers design more selective therapies while limiting damage to healthy tissues.

Subject of Research: CD44’s roles in cancer progression, metastasis, tumour microenvironment interactions, treatment resistance and targeted therapeutic strategies

Article Title: Multifaceted roles of CD44 in cancer progression and targeted therapeutic strategies

Article References: Oh, HJ., Kim, ST., Kim, HJ. et al. “Multifaceted roles of CD44 in cancer progression and targeted therapeutic strategies.” Experimental & Molecular Medicine (2026). https://doi.org/10.1038/s12276-026-01797-x

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01797-x

Keywords: CD44, cancer progression, hyaluronan, cancer stem cells, metastasis, epithelial–mesenchymal transition, tumour microenvironment, drug resistance, targeted therapy, immunotherapy

Mitochondria are not merely energy powerhouses; they are dynamic organelles whose shape, size, and number are tightly regulated through fission and fusion processes. This dynamic equilibrium is critical for maintaining cellular homeostasis, bioenergetics, and the initiation of apoptosis. Proteins like PINK1 and DRP1 are central regulators of mitochondrial quality control and dynamics. PINK1 (PTEN-induced kinase 1) serves as a sensor of mitochondrial health, tagging damaged mitochondria for degradation, whereas DRP1 (Dynamin-related protein 1) mediates mitochondrial fission, facilitating mitochondrial segregation and removal. The interplay between these proteins determines cell fate during stress, and the modulation of their expression facilitates cellular adaptation or triggers apoptosis.

Thymoquinone’s influence on PINK1 and DRP1 protein expression indicates that this compound has a remarkable ability to tip the balance of mitochondrial dynamics toward either repair or destruction pathways. Through meticulous experimentation, the researchers demonstrated altered expression patterns of these proteins in HepG2 and HDF cells following thymoquinone treatment. In cancerous HepG2 cells, which possess altered mitochondrial functions compared to non-cancerous counterparts, thymoquinone triggered changes in PINK1 and DRP1 that favored mitochondrial fission and apoptotic signaling. In contrast, HDF cells exhibited differential sensitivity, highlighting the compound’s selective cytotoxic potential.

Another vital player examined in the study is TFEB (Transcription Factor EB), a master regulator of lysosomal biogenesis and autophagy. TFEB activation has been linked to improved clearance of damaged cellular components, and its modulation is crucial for cellular longevity and stress response. The research reveals that thymoquinone upregulates TFEB expression, potentially enhancing autophagic flux and promoting the removal of dysfunctional mitochondria and cellular debris. This suggests a dual mechanism by which thymoquinone not only promotes mitochondrial fission but also facilitates the clearance of fission products, bolstering cellular quality control pathways.

Cytochrome c, a mitochondrial intermembrane space protein, plays a well-established role in the intrinsic apoptotic pathway. Upon mitochondrial outer membrane permeabilization, cytochrome c is released into the cytosol, where it helps activate caspase cascades culminating in apoptotic cell death. The study provides compelling evidence that thymoquinone initiates cytochrome c release in cancerous HepG2 cells, thereby directly stimulating apoptotic pathways. This finding positions thymoquinone as a potent pro-apoptotic agent capable of selectively inducing cell death in tumor cells through mitochondrial-mediated mechanisms.

By comparing HepG2 and HDF cells’ responses, the researchers uncovered differences in mitochondrial responses to thymoquinone that likely reflect underlying variations in mitochondrial health, bioenergetic states, and stress resistance mechanisms between cancerous and normal cells. These disparities offer a plausible explanation for thymoquinone’s selective toxicity, making it a promising candidate for anticancer therapy with minimal off-target effects on healthy cells. The selective induction of mitochondrial dysfunction and apoptosis in tumorigenic cells could form the basis for future clinical applications.

The implications of these findings extend beyond cancer biology. Given mitochondria’s central role in numerous diseases tied to dysfunctional apoptosis and mitochondrial dynamics, such as neurodegenerative disorders and metabolic syndromes, thymoquinone’s modulatory capacity may have broader therapeutic relevance. Understanding how compounds like thymoquinone reorganize mitochondrial architecture and induce autophagic and apoptotic responses opens new horizons in biomedical research focused on mitochondrial medicine.

Moreover, the study employs state-of-the-art techniques, including quantitative protein expression analysis and advanced imaging, to elucidate the mechanistic pathways underpinning thymoquinone’s effects. This rigorous methodological approach allowed for precise mapping of changes at the mitochondrial level, thereby strengthening the validity of the conclusions drawn. The research team’s ability to dissect these pathways in both cancerous and normal cellular models provides a balanced and comprehensive perspective on the pharmacological potential and safety profile of thymoquinone.

In summary, this pivotal research delivers compelling evidence that thymoquinone induces significant changes in crucial mitochondrial regulators — PINK1, DRP1, TFEB, and cytochrome c. These alterations promote mitochondrial fission, autophagy, and apoptosis, particularly in cancerous HepG2 cells, supporting the compound’s role in mediating tumor suppression through mitochondrial pathways. The differential responses observed in HDF cells highlight the nuanced nature of thymoquinone’s action and hint at its therapeutic specificity.

As the study concludes, the intersection of mitochondrial dynamics and apoptotic signaling emerges as an essential target for anticancer strategies. Thymoquinone, with its natural origin and multi-targeted mode of action, emerges as a novel agent capable of modulating mitochondrial homeostasis and cell fate decisions. Future investigations are poised to expand on these findings, exploring combination therapies and clinical translation while elucidating other potential molecular targets influenced by this potent phytochemical.

This research represents a milestone in understanding mitochondrial regulation by natural compounds and paves the way for harnessing thymoquinone’s biological properties to develop innovative therapeutic interventions. The possibility of leveraging mitochondrial dynamics to achieve selective cancer cell elimination without harming normal cells is a promising frontier in pharmaceutical sciences, with thymoquinone standing at the forefront.

As we deepen our knowledge of mitochondrial biology, the findings of Emrah and Senay provide a paradigm shift in targeting mitochondria-mediated apoptosis through naturally derived substances. Their work charts a compelling course toward novel, safer, and more effective therapies for cancer and possibly other mitochondrial dysfunction-related diseases.

In essence, the investigation into thymoquinone-induced modifications in PINK1, DRP1, TFEB, and cytochrome c bridges molecular biology and clinical potential. It offers exciting prospects for the future of precision medicine, where mitochondrial dynamics are not just cellular processes but therapeutic levers to combat disease.

Subject of Research: The modulation of mitochondrial dynamics and apoptosis by thymoquinone through changes in PINK1, DRP1, TFEB, and cytochrome c expression in human liver cancer (HepG2) and human dermal fibroblast (HDF) cells.

Article Title: Association of thymoquinone-induced changes in PINK1, DRP1, TFEB, and cytochrome c expression with mitochondrial dynamics and apoptosis in HepG2 and HDF cells.

Article References:
Emrah, B., Senay, V.K. Association of thymoquinone-induced changes in PINK1, DRP1, TFEB, and cytochrome c expression with mitochondrial dynamics and apoptosis in HepG2 and HDF cells. Med Oncol 43, 46 (2026). https://doi.org/10.1007/s12032-025-03180-8

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03180-8

Cancer cachexia remains a formidable clinical challenge, marked by profound muscle atrophy and systemic metabolic derangements. Despite its significant impact, the precise molecular players driving the muscle decline have remained elusive. This latest investigation sheds light on how aberrations in intracellular signaling pathways unwrap a cascade of detrimental effects culminating in impaired mitochondrial integrity and function within muscle cells.

The study focuses on the cyclic AMP (cAMP) – protein kinase A (PKA) – cAMP response element-binding protein 1 (CREB1) pathway, a well-known signaling cascade involved in regulating diverse cellular processes including metabolism, gene expression, and cell survival. Normally, activation of this axis ensures mitochondrial biogenesis and optimizes energy production, thereby preserving muscle function. However, through meticulous in vivo and in vitro analyses, the researchers demonstrate that in the context of cancer cachexia, this signaling route is markedly suppressed.

Their data reveal a significant downregulation of cAMP levels in skeletal muscles affected by cachexia, which in turn cripples PKA activity. This reduction leads to decreased phosphorylation and activation of CREB1, an essential transcription factor governing the expression of genes critical for mitochondrial maintenance. Without proper CREB1 function, the muscle cells’ mitochondrial population becomes dysfunctional, losing their efficiency to generate ATP and manage reactive oxygen species.

Importantly, the study delineates that the impaired signaling cascade directly causes structural and functional mitochondrial abnormalities. Electron microscopy images capture the morphological distortions—swollen, fragmented mitochondria with disrupted cristae—mirroring classic signs of mitochondrial stress and dysfunction. These organelle defects compromise cellular energy metabolism, driving the exhausting muscle wasting characteristic of cachexia.

Through transcriptomic profiling, Angelino and colleagues identify a suite of downstream targets regulated by CREB1 that are crucial for mitochondrial dynamics, biogenesis, and oxidative phosphorylation. The suppressed expression of these genes underlies not just mitochondrial structural damage but also the metabolic inflexibility observed in cachectic muscles, locking the cells into a catabolic state that exacerbates muscle breakdown.

In an elegant series of rescue experiments, the team pharmacologically reactivates the cAMP–PKA–CREB1 pathway in murine models of cancer cachexia. Remarkably, restoring this signaling cascade effectively reverses mitochondrial defects, enhancing muscle function and attenuating the cachexia-induced wasting. These findings underscore the therapeutic potential of targeting this signaling axis to preserve muscle integrity in cancer patients.

The implications extend beyond cancer-associated muscle loss since mitochondrial dysfunction is a hallmark of numerous degenerative diseases. The study’s mechanistic insights provide a valuable platform for exploring novel interventions to counteract muscle decline in broader clinical settings, including aging and chronic inflammatory disorders.

Moreover, the research illuminates how systemic factors released by tumors may hijack intracellular signaling within skeletal muscles, suppressing cAMP production and orchestrating bioenergetic collapse. This highlights the intricate crosstalk between tumor biology and host metabolism, deepening our understanding of the systemic nature of cancer cachexia.

By elucidating the precise molecular circuitry that falters during cachexia, this study opens avenues for biomarker development, offering clinicians tools to detect early mitochondrial dysfunction and stratify patients who might benefit from targeted signaling modulators.

As the field advances, translating these preclinical findings into human clinical trials will be crucial to assess the safety and efficacy of interventions aimed at boosting the cAMP–PKA–CREB1 axis. Success in such trials could herald a paradigm shift in managing cancer cachexia, shifting from symptomatic relief to mechanistically driven therapies that address the root cause of muscle deterioration.

This compelling narrative of cellular signaling gone awry during cancer cachexia resonates beyond oncology, emphasizing the universal importance of mitochondrial health in sustaining physiological resilience against catabolic stressors.

The synergy between fundamental molecular biology and translational research showcased here exemplifies the power of integrated approaches to solving pressing biomedical challenges. The work by Angelino et al. stands as a beacon for future studies aiming to unravel the molecular labyrinth governing muscle metabolism in health and disease.

In sum, the impairment of the cAMP–PKA–CREB1 signaling axis emerges as a central driver of mitochondrial failure in skeletal muscle during cancer cachexia, unmasking a promising target to mitigate muscle wasting and improve patient outcomes. This study not only advances our scientific comprehension but also fuels hope for innovative therapies to combat one of the most pernicious complications of cancer.

Subject of Research: Cancer cachexia-induced mitochondrial dysfunction in skeletal muscle mediated by impaired cAMP–PKA–CREB1 signaling.

Article Title: Impaired cAMP–PKA–CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Article References:
Angelino, E., Bodo, L., Sartori, R. et al. Impaired cAMP–PKA–CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01397-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01397-5

The research taps into the ever-expanding field of marine biotechnology, which seeks to uncover natural compounds with therapeutic potential from oceanic biodiversity. Chaetoceros socialis, a unicellular photosynthetic diatom, is traditionally recognized for its ecological role rather than pharmacological properties. Yet, as biotechnology explores nature’s hidden pharmacopeia, compounds such as those extracted from this species emerge as intriguing candidates for targeting malignancies. By employing ethanol as a solvent to yield an extract rich in bioactive molecules, researchers have accessed a complex chemical repertoire capable of interfering with cancer cell homeostasis on multiple fronts.

Prostate cancer and glioblastoma represent two of the most challenging oncological burdens worldwide, both marked by aggressive cellular proliferation and notable resistance to conventional therapies. LNCap cells, derived from metastatic prostate carcinoma, and U-87 MG cells, a widely studied glioblastoma line, serve as robust in vitro models for evaluating anti-cancer efficacy. The study’s demonstration of cytotoxicity—marked decreases in viability—paired with clear indicators of apoptosis, underscores how this marine extract destabilizes survival signaling pathways that cancer cells rely upon to evade death.

At the heart of these pathways lies the AKT/PTEN axis, a crucial regulator of cell growth, metabolism, and survival. AKT kinase activity promotes oncogenic processes, while PTEN acts as a tumor suppressor by negatively regulating AKT. The ethanolic extract from Chaetoceros socialis was shown to modulate this axis, presumably tipping the balance toward PTEN-mediated suppression of AKT activity. Such modulation mitigates proliferative signals, effectively sensitizing cancer cells to apoptosis and halting unchecked growth.

Coupled with this, the mammalian target of rapamycin (mTOR) pathway, a downstream node in cellular signaling that governs protein synthesis and cellular metabolism, also exhibited altered activity. Aberrant mTOR activation is a hallmark of many cancers, including prostate and glioblastoma. By dampening mTOR signaling, the extract potentially disrupts the biosynthetic and anabolic machinery cancer cells harness to sustain rapid proliferation and survival in hostile microenvironments.

In the apoptosis regulatory landscape, the BAX/BCL2 ratio serves as a critical determinant of cell fate. BAX promotes apoptosis by permeabilizing mitochondrial membranes, facilitating cytochrome c release, whereas BCL2 functions antagonistically, inhibiting this process. The study’s findings reveal a shift in the BAX/BCL2 balance toward pro-apoptotic signaling after treatment with the marine extract. This suggests that the compounds contained within the extract instigate mitochondrial-mediated apoptotic mechanisms, reactivating death pathways that cancer cells often suppress to survive.

Further downstream, the activation of Caspase enzymes—the key executors of apoptosis—was noted, signifying that the extract’s pro-apoptotic triggers culminate in the dismantling of cancer cells. Caspase activation leads to systematic cleavage of cellular proteins and DNA fragmentation, hallmarks of irreversible apoptosis. Recognition of these effects in prostate and glioblastoma cell lines—cancers notorious for apoptosis evasion—underscores the therapeutic potential of the bioactive agents found in Chaetoceros socialis.

Importantly, this approach targets multiple regulatory nodes simultaneously, offering a multi-pronged attack that might overcome resistance mechanisms often limiting monotherapeutic interventions. Multi-target strategies are crucial given the genomic and phenotypic heterogeneity of tumors, wherein single-pathway targeting frequently leads to relapse. The extract’s polypharmacological profile could represent a natural prototype for combination treatments or even inspire synthetic analogs designed to emulate its efficacy with optimized pharmacokinetics.

From a broader perspective, these findings spotlight the ocean’s largely untapped reservoir of pharmacologically active substances. Marine microorganisms like diatoms have evolved complex biochemical arsenals to thrive in competitive aquatic ecosystems, often producing compounds with unique structural features not commonly found in terrestrial organisms. The therapeutic translation of these features could redefine cancer treatment paradigms, providing new weaponry against diseases that remain leading causes of mortality globally.

Moreover, the study exemplifies the power of integrating molecular biology techniques with natural product chemistry. By deciphering how an extract influences intracellular signaling circuits, researchers can precisely characterize mechanisms of action, enabling rational development of therapeutic candidates. This mechanistic clarity is vital in drug discovery to predict potential side effects, optimize dosage, and anticipate resistance profiles.

The therapeutic promise revealed here also raises critical questions for subsequent research. Elucidating the exact molecular constituents responsible for the observed bioactivity remains a priority, as crude extracts comprise myriad compounds whose individual and synergistic effects need deconvolution. Furthermore, in vivo validation within animal models will be essential to confirm efficacy, bioavailability, and safety, stepping stones before contemplating clinical trials.

Equally, understanding the pharmacodynamics and pharmacokinetics of the extract’s active components will influence dosing strategies and delivery mechanisms. Given the blood-brain barrier’s notorious restrictiveness, especially relevant for glioblastoma treatment, strategies enhancing central nervous system penetration are crucial if these findings are to translate clinically. Encapsulation technologies or structural modifications might serve to this end.

This line of investigation also intersects with personalized medicine. Tumor heterogeneity requires therapies tailored to specific molecular signatures, and the pathways modulated here—AKT/PTEN, mTOR, BAX/BCL2, Caspases—are variable across patients. Diagnostic tools capable of profiling tumors for these signaling aberrations would complement targeted use of marine-derived compounds, maximizing therapy responsiveness.

From a societal viewpoint, developments like these could reduce reliance on highly toxic chemotherapeutics, offering treatments with potentially fewer side effects due to their natural origin and multi-targeted nature. This aligns with the global agenda towards greener, more sustainable pharmaceutical innovation, underscoring the relevance of ecological conservation and biodiversity preservation.

As research accelerates in this domain, the integration of omics technologies—proteomics, transcriptomics, metabolomics—will deepen understanding of cellular responses to marine extracts, revealing off-target effects and novel molecular intersections. High-throughput screening combined with artificial intelligence-driven drug design could expedite the discovery process, translating marine biology insights into clinical success stories with unprecedented speed.

In conclusion, the presented study offers a compelling narrative of how a seemingly obscure marine microorganism—Chaetoceros socialis—harbors chemical agents with profound anti-cancer activity by rewiring key survival and apoptosis pathways in prostate and glioblastoma cells. This dual modulation of growth inhibition and programmed cell death mechanisms not only rejuvenates natural product research in oncology but also beckons a new era where marine ecosystems contribute front-line therapies against humanity’s deadliest diseases. As the scientific community continues to unravel nature’s complexities, the ocean may well harbor the cures of tomorrow.

Subject of Research: Cytotoxic and pro-apoptotic effects of Chaetoceros socialis ethanolic extract on prostate (LNCap) and glioblastoma (U-87 MG) cancer cells through modulation of the AKT/PTEN, mTOR, BAX/BCL2, and Caspase pathways.

Article Title: In vitro cytotoxic and pro-apoptotic effects of Chaetoceros socialis ethanolic extract on prostate (LNCap) and glioblastoma (U-87 MG) cells via modulation of AKT/PTEN, mTOR, BAX/BCL2, and Caspase pathways.

Article References:
Asoudeh-Fard, A., Jahromi, H.H., Zare, Z. et al. Med Oncol 42, 488 (2025). https://doi.org/10.1007/s12032-025-03034-3

Image Credits: AI Generated